Clínica Universidad de Navarra (CUN)
Centro clínico de la Universidad de Navarra
University Hospital Heidelberg
Heidelberg, AlemaniaUniversity Hospital Heidelberg-ko ikertzaileekin lankidetzan egindako argitalpenak (78)
2024
-
Best original research presented at the 25th European Congress on Gynaecological Oncology: Best of ESGO 2024
International Journal of Gynecological Cancer
-
Clinical practice in European centres treating paediatric posterior fossa tumours with pencil beam scanning proton therapy
Radiotherapy and Oncology, Vol. 198
-
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma
Advances in Therapy, Vol. 41, Núm. 4, pp. 1576-1593
-
Fibroblast activation protein inhibitor-positron emission tomography in aortitis: fibroblast pathology in active inflammation and remission
Rheumatology (United Kingdom), Vol. 63, Núm. 9, pp. 2473-2483
-
Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile
Neuro-oncology, Vol. 26, Núm. 9, pp. 1723-1737
-
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216
2023
-
Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 1, pp. e59-e70
-
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)
Leukemia
-
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
Blood cancer journal
-
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis from the Randomized Phase II ELOQUENT-3 Trial
Journal of Clinical Oncology, Vol. 41, Núm. 3, pp. 568-578
-
Important steps towards a big change for lung health: a joint approach by the European Respiratory Society, the European Society of Radiology and their partners to facilitate implementation of the European Union’s new recommendations on lung cancer screening
ERJ Open Research
-
Overall Survival with Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial
Journal of Clinical Oncology, Vol. 41, Núm. 8, pp. 1590-1599
-
Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600 Mutant Pediatric High-Grade Glioma
Journal of Clinical Oncology, Vol. 41, Núm. 33, pp. 5174-5183
-
The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensus
eClinicalMedicine, Vol. 61
-
Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline
Annals of Oncology, Vol. 34, Núm. 5, pp. 452-467
2022
-
A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells
Cell Metabolism, Vol. 34, Núm. 6, pp. 857-873.e9
-
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781
-
Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322
Annals of oncology : official journal of the European Society for Medical Oncology
-
Corrigendum to “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annals of Oncology 29 suppl. 4 (2018) v238–iv255](S0923753419317119)(10.1093/annonc/mdy308)
Annals of Oncology
-
Corrigendum: “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’”: (Annals of Oncology (2022) 33(1) (117), (S0923753421044999), (10.1016/j.annonc.2021.10.001))
Annals of Oncology